Thomas Patrick Kelly - 15 Oct 2025 Form 3 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship
Chief Financial Officer
Issuer ticker
XENE
Reported as of
15 Oct 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
17 Oct 2025, 18:41:56 UTC
Prior SEC filing
11 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nathaniel Adams, Attorney-in-fact

Key filing fact

Thomas Patrick Kelly filed Form 3 for Xenon Pharmaceuticals Inc. (XENE) on 17 Oct 2025.

Key facts

  • This page summarizes Thomas Patrick Kelly's Form 3 filing for Xenon Pharmaceuticals Inc. (XENE).
  • 0 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 17 Oct 2025, 18:41.

Change

  • Previous filing in this sequence was filed on 11 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001410514 Primary reporting owner

Kelly Thomas Patrick

Relationship
Chief Financial Officer
Address
3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Signature date
17 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENE holding

No securities are beneficially owned.

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
0
Date
15 Oct 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE holding Derivative

No securities are beneficially owned.

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
15 Oct 2025
Ownership
Direct
Underlying class
N/A
Underlying amount
0
Exercise price
$0.000000
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Not applicable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .